SEC Insider Narrative: Foundation Medicine Inc (NASDAQ:FMI) President & COO Steven Kafka, Sold $144,367 in Stock

November 23, 2016 - By Darrin Black

SEC Insider Narrative: Foundation Medicine Inc (NASDAQ:FMI) President & COO Steven Kafka, Sold $144,367 in Stock

Steven Kafka Insider Sell

Mr. Steven Kafka, the current President & COO at Foundation Medicine Inc has recently been involved with a transaction of 6,273 shares of the company, valued at $23.0 per share. The amount of the trade was of $144,367 U.S Dollars. Steven is trying to silently decrease his company’s share, same as he did in the last month. He sold another 5,427 shares worth $124,821 USD. Right now, he has in hand 101,550 shares or exactly 0.29% of Foundation Medicine Inc’s market capitalization (total value of the shares outstanding). The information is as revealed in a SEC Form 4 dated 22/11/2016.

Foundation Medicine Inc (NASDAQ:FMI) Ratings Coverage

Out of 8 analysts covering Foundation Medicine (NASDAQ:FMI), 0 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 0 are positive. $30 is the highest target while $19 is the lowest. The $24.33 average target is 6.01% above today’s ($22.95) stock price. Foundation Medicine has been the topic of 10 analyst reports since July 30, 2015 according to StockzIntelligence Inc. As per Thursday, July 30, the company rating was downgraded by JMP Securities. BTIG Research initiated the shares of FMI in a report on Monday, September 14 with “Buy” rating. The stock of Foundation Medicine Inc (NASDAQ:FMI) earned “Neutral” rating by UBS on Wednesday, September 21. The stock has “Neutral” rating given by BTIG Research on Wednesday, November 4. The rating was downgraded by Benchmark on Thursday, November 3 to “Hold”. The stock of Foundation Medicine Inc (NASDAQ:FMI) has “Market Perform” rating given on Wednesday, September 16 by Wells Fargo.

Insitutional Activity: The institutional sentiment decreased to 1.67 in 2016 Q2. Its down 0.10, from 1.77 in 2016Q1. The ratio worsened, as 10 funds sold all Foundation Medicine Inc shares owned while 16 reduced positions. 4 funds bought stakes while 42 increased positions. They now own 10.32 million shares or 3.75% less from 10.73 million shares in 2016Q1.

Teacher Retirement System Of Texas, a Texas-based fund reported 1,909 shares. Commerzbank Aktiengesellschaft Fi last reported 0% of its portfolio in the stock. Blackrock Inv Ltd has invested 0% of its portfolio in Foundation Medicine Inc (NASDAQ:FMI). Lord Abbett And Com Lc holds 0.01% or 210,912 shares in its portfolio. Blackrock Advisors Limited Liability last reported 0% of its portfolio in the stock. The New York-based Int Grp Inc has invested 0% in Foundation Medicine Inc (NASDAQ:FMI). Geode Mngmt Lc last reported 0% of its portfolio in the stock. Moreover, Blair William Il has 0.01% invested in Foundation Medicine Inc (NASDAQ:FMI) for 70,040 shares. State Street last reported 201,473 shares in the company. Nationwide Fund Advsrs owns 8,493 shares or 0% of their US portfolio. Moreover, Legal And General Grp Incorporated Public Ltd Company has 0% invested in Foundation Medicine Inc (NASDAQ:FMI) for 2,227 shares. Comml Bank Of America Corp De reported 3,032 shares or 0% of all its holdings. Baillie Gifford & accumulated 0.01% or 174,800 shares. Bnp Paribas Arbitrage Sa last reported 0% of its portfolio in the stock. State Treasurer State Of Michigan owns 12,000 shares or 0% of their US portfolio.

Insider Transactions: Since July 1, 2016, the stock had 0 insider buys, and 15 insider sales for $1.46 million net activity. The insider Kafka Steven J. sold $241,600. The insider Pellini Michael J sold $62,176. On Monday, October 3 Miller Vincent A. sold $31,581 worth of the stock or 1,342 shares. Daly David also sold $11,284 worth of Foundation Medicine Inc (NASDAQ:FMI) on Thursday, September 1. On Friday, August 19 the insider Ryan Jason sold $331,614. $28,853 worth of shares were sold by Hesslein Robert W. on Tuesday, October 4.

The stock increased 0.88% or $0.2 during the last trading session, hitting $22.95. About 110,462 shares traded hands. Foundation Medicine Inc (NASDAQ:FMI) has risen 31.44% since April 21, 2016 and is uptrending. It has outperformed by 26.11% the S&P500.

Foundation Medicine, Inc. is a molecular information company. The company has a market cap of $808.15 million. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. It currently has negative earnings. The Company’s segment is the business of delivering molecular information about cancer to its customers.

According to Zacks Investment Research, “Foundation Medicine, Inc. provides molecular information products primarily in the United States. The company offers FoundationOne(TM) a molecular information product for the analysis of routine cancer specimens in a clinical setting. Its molecular information platform generates actionable genomic information about a patient’s individual disease, enabling physicians to optimize treatments in clinical practice, and enabling biopharmaceutical companies to develop targeted oncology therapies. Foundation Medicine, Inc. is based in Cambridge, Massachusetts.”

More news for Foundation Medicine Inc (NASDAQ:FMI) were recently published by: Businesswire.com, which released: “Foundation Medicine Announces Commercial Launch of Liquid Biopsy Assay ..” on May 03, 2016. Businesswire.com‘s article titled: “Foundation Medicine Adds New Immunotherapy Features to Its Market-Leading Products” and published on August 22, 2016 is yet another important article.

FMI Company Profile

Foundation Medicine, Inc., incorporated on November 12, 2009, is a molecular information company. The Firm sells products that are enabled by its molecular information platform to physicians and biopharmaceutical companies. The Company’s segment is the business of delivering molecular information about cancer to its customers. The Company’s platform includes various methods and algorithms for analyzing specimens across various types of cancer, and for incorporating that information into clinical care. The Company’s products provide genomic information about each patient’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. The Company’s flagship clinical molecular information products, FoundationOne for solid tumors, and FoundationOne Heme for blood cancers or hematologic malignancies, including leukemia, lymphoma, myeloma and advanced sarcomas, are genomic profiles designed for use in the routine care of patients with cancer.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Tags: , ,

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>